<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Graul EL</submitter><funding>Medical Research Council</funding><funding>NIHR Imperial Biomedical Research Centre</funding><funding>National Institute for Health Research (NIHR)</funding><pagination>ooad078</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10463548</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>6(3)</volume><pubmed_abstract>&lt;h4>Objective&lt;/h4>To develop a standardizable, reproducible method for creating drug codelists that incorporates clinical expertise and is adaptable to other studies and databases.&lt;h4>Materials and methods&lt;/h4>We developed methods to generate drug codelists and tested this using the Clinical Practice Research Datalink (CPRD) Aurum database, accounting for missing data in the database. We generated codelists for: (1) cardiovascular disease and (2) inhaled Chronic Obstructive Pulmonary Disease (COPD) therapies, applying them to a sample cohort of 335 931 COPD patients. We compared searching all drug dictionary variables (A) against searching only (B) chemical or (C) ontological variables.&lt;h4>Results&lt;/h4>In Search A, we identified 165 150 patients prescribed cardiovascular drugs (49.2% of cohort), and 317 963 prescribed COPD inhalers (94.7% of cohort). Evaluating output per search strategy, Search C missed numerous prescriptions, including vasodilator anti-hypertensives (A and B:19 696 prescriptions; C:1145) and SAMA inhalers (A and B:35 310; C:564).&lt;h4>Discussion&lt;/h4>We recommend the full search (A) for comprehensiveness. There are special considerations when generating adaptable and generalizable drug codelists, including fluctuating status, cohort-specific drug indications, underlying hierarchical ontology, and statistical analyses.&lt;h4>Conclusions&lt;/h4>Methods must have end-to-end clinical input, and be standardizable, reproducible, and understandable to all researchers across data contexts.</pubmed_abstract><journal>JAMIA open</journal><pubmed_title>Determining prescriptions in electronic healthcare record data: methods for development of standardized, reproducible drug codelists.</pubmed_title><pmcid>PMC10463548</pmcid><funding_grant_id>COV-LT-0009</funding_grant_id><funding_grant_id>MC_PC_20059</funding_grant_id><funding_grant_id>HDR-23004</funding_grant_id><pubmed_authors>Graul EL</pubmed_authors><pubmed_authors>Stone PW</pubmed_authors><pubmed_authors>Denaxas S</pubmed_authors><pubmed_authors>Massen GM</pubmed_authors><pubmed_authors>Hatam S</pubmed_authors><pubmed_authors>Peters NS</pubmed_authors><pubmed_authors>Quint JK</pubmed_authors><pubmed_authors>Adamson A</pubmed_authors></additional><is_claimable>false</is_claimable><name>Determining prescriptions in electronic healthcare record data: methods for development of standardized, reproducible drug codelists.</name><description>&lt;h4>Objective&lt;/h4>To develop a standardizable, reproducible method for creating drug codelists that incorporates clinical expertise and is adaptable to other studies and databases.&lt;h4>Materials and methods&lt;/h4>We developed methods to generate drug codelists and tested this using the Clinical Practice Research Datalink (CPRD) Aurum database, accounting for missing data in the database. We generated codelists for: (1) cardiovascular disease and (2) inhaled Chronic Obstructive Pulmonary Disease (COPD) therapies, applying them to a sample cohort of 335 931 COPD patients. We compared searching all drug dictionary variables (A) against searching only (B) chemical or (C) ontological variables.&lt;h4>Results&lt;/h4>In Search A, we identified 165 150 patients prescribed cardiovascular drugs (49.2% of cohort), and 317 963 prescribed COPD inhalers (94.7% of cohort). Evaluating output per search strategy, Search C missed numerous prescriptions, including vasodilator anti-hypertensives (A and B:19 696 prescriptions; C:1145) and SAMA inhalers (A and B:35 310; C:564).&lt;h4>Discussion&lt;/h4>We recommend the full search (A) for comprehensiveness. There are special considerations when generating adaptable and generalizable drug codelists, including fluctuating status, cohort-specific drug indications, underlying hierarchical ontology, and statistical analyses.&lt;h4>Conclusions&lt;/h4>Methods must have end-to-end clinical input, and be standardizable, reproducible, and understandable to all researchers across data contexts.</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Oct</publication><modification>2026-05-29T05:54:04.955Z</modification><creation>2025-04-19T06:47:13.843Z</creation></dates><accession>S-EPMC10463548</accession><cross_references><pubmed>37649988</pubmed><doi>10.1093/jamiaopen/ooad078</doi></cross_references></HashMap>